p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
J. Luo, Z. Chen, Y. Qiao, J. C.-Y. Tien, E. Young, R. Mannan, S. Mahapatra, T. He, S. Eyunni, Y. Zhang, Y. Zheng, F. Su, X. Cao, R. Wang, Y. Cheng, , A. M. Chinnaiyan
This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.
bioRxiv · Mar 29, 2024Cancer Biology